Td Asset Management Inc Stoke Therapeutics, Inc. Transaction History

Td Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	SELL	$12.56 - $22.53 $107,111 - $192,135	-8,528 Reduced 24.57%	26,186 $341,000
Q4 2021 Feb 10, 2022	BUY	$18.11 - $30.72 $101,416 - $172,032	5,600 Added 19.23%	34,714 $833,000
Q2 2021 Aug 11, 2021	SELL	$30.53 - $41.09 $241,187 - $324,611	-7,900 Reduced 21.34%	29,114 $834,000
Q1 2021 May 14, 2021	BUY	$36.08 - $69.81 $204,681 - $396,032	5,673 Added 18.1%	37,014 $1.44 Million
Q4 2020 Feb 16, 2021	BUY	$33.62 - $61.93 $304,664 - $561,209	9,062 Added 40.68%	31,341 $1.94 Million
Q1 2020 May 15, 2020	BUY	$16.8 - $34.15 $40,320 - $81,960	2,400 Added 12.07%	22,279 $510,000
Q3 2019 Nov 07, 2019	BUY	$20.53 - $37.72 $408,115 - $749,835	19,879 New	19,879 $427,000

125

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $367M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.